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Background: This study was conducted to determine if anti-tumor vaccination administered prior to partial
debulking surgery could improve survival using a murine solid tumour model.
Methods: Tumor incidence and survival rates were compared in mice bearing subcutaneous AB1-HA mesothelioma
tumors that received either sham surgery, debulking surgery or vaccination prior to debulking surgery. Additionally,
mice were depleted of CD4 and/or CD8 T lymphocytes during vaccination to assess their involvement in vaccine
induced anti-tumor immunity. Flow cytometry was performed to characterise changes in the proportion and
activation status of immune cells associated with anti-tumor immunity.
Results: Neoadjuvant vaccination combined with debulking surgery resulted in decreased tumor burden, increased
survival and generation of tumor-specific immunity compared to surgery alone. Depletion of CD8 T cells completely
abrogated any vaccine induced anti-tumor immune response. Conversely, CD4 depletion enhanced CD8 T cell
activation resulting in complete tumor regression in 70% of mice treated with combined surgery and vaccination
therapy. Tumor free survival was associated with established immunological memory as defined by the induction of
effector memory T cells and resistance to rechallenge with parental AB1 mesothelioma cells.
Conclusions: Neoadjuvant anti-cancer vaccination combined with partial debulking surgery induced
CD8-dependent anti-tumor immunity that significantly delayed tumor outgrowth relative to surgery alone.
Complete tumor eradication was observed when vaccination and surgery were performed in CD4 T cell depleted
animals. This demonstrates that adjuvant immunotherapy can improve post-surgical survival following cancer
debulking surgery and provides a scientific rational for clinical trials of such an approach.
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Surgery is a widely used therapy for many common solid
tumors, including thoracic malignancies such as non-
small cell lung cancer and in some patients with ma-
lignant mesothelioma [1,2]. However, surgery alone is
often not curative, as these cancers commonly relapse
due to local recurrence of unresectable tumor or growth
of distant metastases. While adjuvant chemotherapy or* Correspondence: scott.fisher@uwa.edu.au
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unless otherwise stated.radiotherapy is often used post-surgery to eradicate sub-
clinical distant metastases or residual local disease, these
therapies result in limited survival benefits [3–6]; high-
lighting the need for the development of better adjuvant
therapies.
In the last decade there has been considerable im-
provement in our understanding of the interaction be-
tween the host immune system and developing tumor.
This has encouraged many researchers to revisit the use
of adjuvant immunotherapies to target residual tumor
mass. We have previously demonstrated delayed tumor
development after combining debulking surgery with an-
titumor immunotherapy [7–9] and successfully used au-
tologous tumor lysate as an effective anti-cancer vaccine
[10,11]. Vaccination against known tumor antigens alsotd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Fisher et al. Journal of Translational Medicine 2014, 12:245 Page 2 of 9
http://www.translational-medicine.com/content/12/1/245represents an appealing therapeutic option for the eradi-
cation of residual tumor following debulking surgery
with different tumor vaccine protocols showing promise
in a variety of preclinical models [12–15] and cancer
vaccines continue to be clinically evaluated for a range
of solid cancers (reviewed in [16–18]).
However, understanding when to vaccinate in relation
to surgery may have a significant impact on the outcome
of the treatment. In a murine model of melanoma, neo-
adjuvant vaccination (i.e. prior to surgery) was shown to
provide superior protection against post-surgical tumour
relapse compared to adjuvant vaccination [13]. The
authors assessed the presence and frequency of the
key cell types associated with effective anti-tumor im-
munity (namely CD8 and CD4 T lymphocytes) and
found that neoadjuvant vaccination enables surgery
to coincide with the peak of the vaccine induced im-
mune response, resulting in increased frequency tumor-
specific CD8 T cells present in the tumor, lymph nodes
and resection area. In this study we have chosen murine
mesothelioma as the model because the tumors mimic
their human counterparts molecularly, biologically and
clinically and their immunological engagement with
the host before and after surgery has been well defined
[7–9]. Importantly, they appear to be sensitive to im-
munotherapy and, as some patients undergo debulking




All reagents were purchased from Sigma Aldrich (Castle
Hill, NSW. Australia) unless stated otherwise. Female
BALB/C (H-2Kd) aged between 6 and 8 weeks were ob-
tained from the Animal Resources Centre (Murdoch,
Western Australia). All mice were maintained under
standard specific pathogen free (SPF) housing conditions
and all animal experiments were carried out according
to protocols approved by the University of Western
Australia Animal Ethics Committee.
Mouse model: tumor inoculation and surgical resection of
tumors
Mice were inoculated subcutaneously (s.c.) with 5×105
AB1-HA cells in a total volume of 100 μl PBS on the
right hand flank unless otherwise stated. For all ex-
periments mice were randomised into groups of 5 once
tumors were established (approximately 50–70 mm2).
Mice were culled when tumors reached the maximum
allowable size of 100 mm2 as per UWA AEC approvals.
All surgical resections were performed under general an-
aesthetic using inhalant isoflurane. As a control for the
surgical process sham surgery was performed by making
incisions into the tumor mass and re-suturing, withoutdebulking. Debulking surgery was performed via elliptic
incisions, centred over the s.c. tumors. Skin flaps were
elevated to expose adherent tumors. Once tumors were
dissected clear of adjacent fascia, 75% of the tumor mass
was removed, with preservation of the tumor pedicles
to ensure blood supply (as previously described [19]).
Wounds were closed using 4–0 vicryl (polyglactin 910,
Ethicon, Australia) continuous sutures. Mice received
0.1 mg/kg buprenorphine intraperitoneally (i.p.) in the
recovery phase for postoperative analgesia as required.
Cell lines & vaccines
The murine mesothelioma cell line (AB1) was generated
by injecting crocidolite asbestos i.p. into BALB/C mice
as previously described [20] and subsequently trans-
fected with the PR8 influenza virus haemagglutinin (HA)
gene to produce AB1-HA [21].
Mouse adapted Influenza virus (PR/8/34/H1N1) was a
kind gift from Dr Peter Henry (UWA School of Pharma-
cology, Perth Western Australia). PR8 virus was propa-
gated in the allantoic fluid of 9-day old embryonated
chicken eggs (Altona Hatchery, Forrestfield, Australia) at
37°C for 3 days and harvested as previously described
[22], stored in single use aliquots at −80°C and diluted
1:100 to 1:400 in sterile PBS prior to intranasal vaccin-
ation of mice.
Generation of recombinant Modified Vaccinia Ankara
expressing Influenza HA antigen. PR8 Influenza HA
from the AB1-HA cell line was cloned via RT-PCR into
pCR4 cloning vector using the pZeroBlunt-TOPO clon-
ing kit. PCR primers were designed to introduce a Pme I
restriction site and add a 6HIS-3xSTOP-Asc I sequence
to the 5′ and 3′ end of the HA cds respectively. The
Pme I/Asc I flanked HA-6HIS insert from pCR4-HA was
then cloned into the modified Vaccinia Ankara (MVA)
shuttle vector pZWIGR3 [23] to produce pZWIGR3-
HA. To generate recombinant MVA (rMVA) express-
ing HA, pZWIGR3-HA was transfected into wild type
MVA (wtMVA) infected BHK-21 cells and rMVA-HA
positive cells purified via sequential rounds of plaque
purification based on expression of the fluorescent re-
porter Venus. The purity of rMVA-HA stocks was
confirmed by the absence of wtMVA and presence of
HA via PCR prior to expansion and ultra-purification
of rMVA-HA stocks for experimental use. All rMVA-HA
vaccinations were via i.p. injection in a total volume of
100 μl PBS containing 5×105 plaque forming units of
virus.
Flow cytometry and antibodies
Flow cytometry was performed using a BD Canto II.
All antibodies are anti-mouse unless otherwise stated.
Flow cytometry: αCD3-PE-Cy7 (clone 145-2C11), αCD4-
PerCP-Cy5.5 (clone GK1.5), αCD8-FITC (clone 53–6.7)
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USA; αCD8-APC-ef780 (clone 53–6.7), αFoxP3-FITC
(clone FJK-16 s), αIFNγ-APC (clone XMG1.2), αCD44-
PerCP-Cy5.5 (clone IM7), αCCR7-PE (clone 4B12) and
αCD62L-APC (Clone MEL-14) all eBioscience, USA;
αKi67-PE (clone B56) (BD Biosciences, USA) and HA-
Dextramer-APC (Immudex USA, LLC. Virginia USA). For
depletion experiments, purified αCD4 (GK1.5) and αCD8
(YTS.169) antibodies were obtained from Absolutions Pty
Ltd (Western Australian Institute for Medical Research,
Perth, Western Australia). Antibodies were administered
by intravenous (i.v.) injection at a dose of 150 μg per
mouse on day 1 and then 100 μg i.p. per mouse every
third day as indicated. T cell subset depletion was con-
firmed by flow cytometry on peripheral blood samples.
Statistical analysis
Student’s t test was used to measure significance between
two individual groups, Log rank analysis was performed
on survival curves. All analysis was performed using
Graph Pad Prism Software (Graph Pad Software Inc., CA,
USA) and a p value <0.05 considered significant.
Results
Neoadjuvant vaccination delays tumor growth following
debulking surgery
We have previously demonstrated that partial, but not
complete debulking surgery promotes protective anti-
tumour immunity when combined with adjuvant im-
munotherapy [7]. This is despite complete resection pre-
venting any relapse of residual tumor growth [19]. We
have continued to refine our model of tumor debulking
by investigating the effect of removing different amounts
of tumor on the rate of residual tumor outgrowth and
overall survival (Khong et al., manuscript in preparation)
When 75% of the tumor was debulked we observed that
the outgrowth of the residual tumor was relatively slow,
while in contrast, removing 50% or less of the tumor
had no effect on tumor outgrowth. We therefore chose a
75% debulk model for this study as it better represents
the many clinical scenarios where debulking surgery is
the realistic goral rather than complete resection.
To determine whether the addition of PR8 prime and
rMVA-HA boost (P/B) vaccination directed against the
HA-neo tumour antigen (as describe above) could im-
prove the survival benefit associated with debulking sur-
gery, groups of AB1-HA tumor bearing mice were
treated with either sham surgery (tumor incised, but not
debulked), 75% debulking surgery, prime boost vaccin-
ation or a combination of neoadjuvant vaccination and
surgery (Figure 1A). A significant delay in tumor growth
(p < 0.001) was observed for surgery combined with vaccin-
ation group relative to other treatment groups. (Figure 1B).
Groups receiving vaccination (alone or in combinationwith surgery) had noticeably smaller tumors on the day
of surgery and a significantly higher proportion of inter-
feron gamma (IFN-γ) expressing tumor-specific CD8 T
cells when compared to non-vaccinated groups one
week after vaccination (Figure 1D). However, despite all
vaccinated groups demonstrating the presence of a func-
tional tumour-specific CD8 T cell immune response, only
the combination of neoadjuvant vaccination and 75%
debulking surgery was associated with significantly de-
layed tumor growth and increased significant survival
benefit (p < 0.001) relative to surgery or vaccination alone
(Figure 1B).CD4 T cell depletion during vaccination results in
significant survival benefit following debulking surgery
We hypothesised that the delay in tumor growth in vac-
cinated mice resulted from a vaccine induced anti-tumor
immune response. To test this, we depleted two known
key anti-tumour immune effector cell types, CD4 and
CD8 T lymphocytes, during vaccination and compared
the overall survival of each group (Figure 2A). Consist-
ent with our earlier experiments, we observed a delay in
tumor growth that was associated with a significant sur-
vival benefit (p < 0.01) when neoadjuvant vaccination
was combined with 75% debulking surgery compared to
surgery alone; although this was not sufficient to prevent
tumor outgrowth. Depletion of CD8 T cells, either alone
or in combination with CD4 T cells, completely abro-
gated any vaccine induced survival benefit, reducing the
survival of CD8-depleted groups to that of the surgery
only group (Figure 2A), indicating that CD8 T cells are
essential for an effective anti-tumor immune response.
Similarly, CD4 depletion during vaccination prevented
any vaccine induce delay in tumor growth prior to sur-
gery. However, in contrast to the combined surgery and
vaccine group, in which all mice eventually succumb
to tumor, we observed complete tumor eradication in
60% of CD4 depleted mice following debulking surgery
(Figure 2A). Further experiments confirmed that CD4
depletion either prior to surgery, or during vaccination
was sufficient to eradicate tumor in 50% (5/10) of trea-
ted animals and this could be increased to 70% (7/10)
when vaccination was combined with surgery (Figure 2B),
demonstrating that vaccination with CD4 depletion sig-
nificantly enhances survival compared to surgery alone.
In both sets of experiments all mice survived tumor-free
for longer than 60 days post-surgery. In addition, they
resisted rechallenge with the parental tumor cell-line
that does not express HA (black arrow, Figure 2A & B),
indicating that the vaccine-induced immune response
was against shared tumor antigens on the AB1 meso-
thelioma cells and not solely against the transfected HA
antigen.
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Figure 1 Neoadjuvant P/B vaccination enhances delay in tumor growth following debulking surgery. (A) Schematic of experiment design.
BALB/c mice bearing AB1-HA tumor received PR8 prime vaccine (day 10) and rMVA-HA boost vaccine (day 17) alone, in combination with surgery
(day 18) and tumor growth and overall survival compared to surgery only or sham surgery control groups. (B) Survival and growth curves
showing significant survival benefit with combined therapy. (C-D) An increase in the proportion (C) and function (D) of HA-specific CD8 T cells
was only observed in the spleens of vaccinated mice on day 21. **p < 0.01, ***p < 0.001. dLN = draining lymph node. ndLN = non-draining lymph
node. Data =mean + SEM.
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establishes immunological protection
Having demonstrated that CD8 T cells were essential for
effective anti-tumor immunity, we next assessed the im-
munological effect of CD4 depletion on CD8 T cells.
Peripheral blood taken from mice during CD4 T cell de-
pletion (days 7, 10, 15 and 22, shown in Figure 2B) was
analysed by polychromatic flow cytometry to assess theproportion and activation status (ICOS expression) of T
cell subsets. The proportion of CD4 and CD8 (as a per-
centage of total CD3+ lymphocytes) and FoxP3 + CD4+
regulatory T cells (Treg, as a proportion of total CD4+ T
cells) was as expected, the same in all groups at baseline
(day 7) and remained unchanged throughout the experi-
ment in all non-CD4 depleted groups (Figure 3). In con-




















































Figure 2 Depletion of CD4 T cells during neoadjuvant vaccination significantly improves survival outcome after debulking surgery. All
groups of AB1-HA bearing BALB/c mice (n = 10) received 75% debulking surgery on day 18 (dotted line). Vaccinated mice received rMVA-HA i.p.
7 days apart (P/B) and depleting antibodies (black arrows) were given every 3 days, starting 1 day prior to the first vaccination (q3dx4). Surviving
mice were rechallenged on day 81 (black triangle). (A) Tumor growth and survival data showing delay in tumor growth after combined therapy
compared to surgery only. Complete tumor regression was only observed when combined therapy was performed in the absence of CD4 T cells
(open triangle). (B) Data from repeat experiments showing overall survival following surgery or vaccination as individual or combined therapies,
with or without CD4 T cell depletion. Depletion of CD4 T cells significantly improved the survival outcome relative to non-depleted controls. All
surviving mice resisted tumor rechallenge. **p < 0.01, ***p < 0.001. All significant Logrank comparison are to respective untreated controls.
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(p < 0.0001), correlating with a significant increase in
the proportion and activation status of CD8 T cells
(Figure 3C-D, p < 0.0001). Sustained CD8 T cell activation
was observed in CD4 depleted groups, coinciding with
tumor regression (days 22–35) and ultimately long term
survival (Figure 2B). CD4 T cell depletion was transient
and had returned to baseline levels by day 81 when surviv-
ing mice were rechallenged with parental tumour (data
not shown). Again, all surviving mice resisted rechallenge
and remained tumor free until completion of the experi-
ment (day 154). Establishment of immunological memory
was consistent with the finding of a significant increase in
CD44+ CD62L- effector memory T cells (TEM) in the
spleen and lymph nodes of CD4 depleted groups at day
140 relative to naïve bearing controls (Figure 4).Discussion
Although surgery remains the most effective treatment
option for many solid malignancies, regrowth of residual/
non-resectable tumor or growth of distal metastases
means that surgery is not always curative, highlighting the
need to develop improved, combinatorial treatment strat-
egies. Over the past decade our knowledge of how the im-
mune system recognises and interacts with developing
tumor has greatly expanded (reviewed in [2,24,25]), driv-
ing a renewed interest in utilising adjuvant immunother-
apies in the treatment of solid tumors. One key question
is whether new immunotherapies can add value to tumor
debulking surgery.
In this study we assessed the impact of neoadjuvant
vaccination in combination with partial debulking sur-



































































































































































Figure 3 Enhanced CD8 T cell activation following CD4 Depletion. Flow cytometry analysis of pre (baseline) and post-treatment (day 22)
peripheral blood lymphocytes taken from the same mice shown in Figure 2B. (A-B) The relative proportion and activation (ICOS) status of CD4,
CD8 and Treg (CD4 + FoxP3+) lymphocyte subsets were similar between all groups prior to treatment. (C-D) CD4 T cell depletion resulted in a
significant increase (****p < 0.0001) in the relative proportion and activation status of CD8 T cells (black squares) compared to the respective
non-CD4 depleted groups.
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represents an ideal tumor for clinical translation. We
found that vaccination induced a significant increase in
CD8+ cytotoxic T lymphocytes (CTL), a key type of ef-
fector cell in anti-tumor immune responses [25]. While
surgery or vaccination alone delayed tumor growth rela-
tive to controls, a significant survival benefit was only
observed when surgery and vaccination were combined.
However, unlike Grinshtein et al., who showed that neo-
adjuvant vaccination protected against tumor regrowth
after complete surgical resection [13], we observed that
combined treatment could not prevent tumor outgrowth
in our model. Instead, complete tumor eradication was
only observed when combined vaccination and sur-
gery was performed in the absence of CD4 T cells. While
differences between models and vaccination protocols
make it hard to directly compare our results, it isknown that mesotheliomas secrete immunosuppres-
sive cytokines such as TGF-β that may limit vaccine
induced anti-tumour immunity in the tumor environ-
ment [26,27].
The requirement for CD4 T cell depletion suggests a
role for regulatory T cells in limiting vaccine induced
anti-tumour immunity. Treg are a subset of CD4+ T
cells and are recognised as important negative regulators
of immune responses [28]. Treg have been shown to
promote tumor growth by limiting the efficacy of
tumor-specific CD8 T cell responses and their presence
within the tumour infiltrate has been correlated with
poor survival prognosis for a number of different malig-
nancies (reviewed in [29]). Therefore, consistent with
our findings, vaccination protocols that involve Treg de-
pletion or inhibition of their immunosuppressive func-































Figure 4 Enhanced immunological memory following CD4 T cell depletion. Polychromatic flow cytometry was used to determine the
proportion of CD8+ CD44+ CD62L- effector memory (TEM) T cells in spleen (Spln) and lymph nodes (LN) of the tumor rechallenged mice
from Figure 2B. Significantly more TEM were observed in LN and Spln from all CD4 depleted groups compared to control mice. * = p <0.05,
***p < 0.001, ****p < 0.0001.
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be achieved in a clinical setting. To date cyclophospha-
mide has been extensively studied for its ability to en-
hance anti-tumour immunity, including anti-tumour
vaccination, by reducing Treg when used at low doses
[30–34]. Conversely, high dose cyclophosphamide is
lymphodepletive [35,36] and while the use of high dose
cyclophosphamide in combination with total body irradi-
ation is critical to increase the effectiveness of adoptive
cell therapy (ACT) treatment of melanoma patients
[37,38], it is not without associated toxicity and the re-
quirement of CD4 depletion during ACT has been ques-
tioned [39].
Recent studies have also shown that targeting the
surface receptors cytotoxic T-lymphocyte antigen 4
(CTLA-4) and programmed death-1 (PD-1) on both ef-
fector and regulatory T cells, a process known as check-
point blockade, can dramatically improve anti-tumor
immunity [40–44], especially in advanced stage melan-
oma [45–47]. These new advances in immunotherapy
suggest a role for adjuvant immunotherapy to be in-
cluded in anti-cancer vaccination protocols, particularly
when combined with conventional treatments such as
debulking surgery.
Taken together, this study demonstrates that neo-
adjuvant anti-tumor vaccination combined with partial
debulking surgery is capable of inducing effective CD8
T cell dependent anti-tumor immunity. Furthermore,
depletion of CD4 T cells during vaccination produced
complete tumor eradication and established immuno-
logical memory that could protect against subsequent
tumor growth.Conclusions
These results suggest that prior to performing debulking
surgery, administration of an immunotherapy consisting
of transient CD4 T cell, or more specifically Treg de-
pletion combined with anti-tumor vaccination is an ef-
fective therapeutic strategy to enhance survival. These
results provide a logical basis for development of adju-
vant immunotherapies for patients undergoing cancer
surgery in whom complete tumor resection is not likely
to be achieved, or who may achieve complete resection,
but at high risk or relapse.
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